Healthcare Services

Nasal Spray Influenza Vaccine Market Outlook 2026–2030 Exploring New Business Opportunities

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Nasal Spray Influenza Vaccine Market Evolve From 2026 To 2030?

The nasal spray influenza vaccine market has experienced rapid expansion in recent years. Forecasts indicate it will increase from $1.48 billion in 2025 to $1.66 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 12.7%. Historically, this expansion has been driven by factors such as heightened awareness of flu vaccination, a strong reliance on conventional injection-based flu vaccines, various government-led influenza immunization initiatives, occurrences of seasonal flu outbreaks, and the restricted availability of alternative needle-free options.

The market for nasal spray influenza vaccines is projected to experience swift expansion over the coming years. This market is anticipated to reach $2.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.7%. Factors driving this growth during the forecast period include an increasing demand for needle-free administration methods, the broadening scope of immunization programs for both pediatric and geriatric populations, heightened investment in nasal vaccine research and development, the creation of sophisticated attenuated vaccine formulations, and expanding global efforts to boost vaccination coverage. Key trends observed during the forecast period encompass the increasing embrace of needle-free vaccination techniques, a surging demand for influenza vaccines suitable for children, the wider application of quadrivalent live attenuated vaccines, a rise in campaigns aimed at preventing seasonal flu, and the innovation of both multi-dose and single-dose nasal formulations.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24326&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Nasal Spray Influenza Vaccine Market?

The escalating occurrence of influenza is anticipated to fuel the expansion of nasal spray influenza vaccine going forward. Influenza, a highly infectious viral condition, primarily impacts the respiratory system, leading to symptoms like fever, cough, sore throat, body aches, and fatigue. The rising incidence of influenza stems mainly from the frequent genetic changes in the influenza virus, allowing it to bypass existing immunity and disseminate quickly across populations. The nasal spray influenza vaccine offers protection against influenza by introducing a weakened version of the virus directly into the nasal passages, thereby prompting an immune reaction at the typical entry point of the virus. For instance, in September 2024, data from the Centers for Disease Control and Prevention (CDC), a US-based nation’s health protection agency, indicated that preliminary figures for the 2023–2024 U.S. influenza season showed between 34 million and 75 million symptomatic illnesses, 15 million to 33 million medical visits, 380,000 to 900,000 hospitalizations, and 17,000 to 100,000 deaths, with older adults (=65 years) constituting 51% of hospitalizations and 68% of deaths. Consequently, the growing prevalence of influenza is propelling the growth of the nasal spray influenza vaccine market.

Which Segment Areas Are Covered In The Nasal Spray Influenza Vaccine Market Analysis?

The nasal spray influenza vaccine market covered in this report is segmented –

1) By Type: Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine

2) By Administration Method: Single-Dose Administration, Multi-Dose Administration

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Online Stores, Other Distribution Channels

5) By End User: Healthcare Providers, Individuals, Government Health Departments, Pharmaceutical Companies

Subsegments:

1) By Live Attenuated Influenza Vaccine (LAIV): Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV), Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)

2) By Inactivated Influenza Vaccine: Whole Virus Inactivated Vaccine, Split Virus Inactivated Vaccine, Subunit Inactivated Vaccine, Adjuvanted Inactivated Vaccine, High-Dose Inactivated Vaccine

Which Trends Are Shaping The Future Of The Nasal Spray Influenza Vaccine Market?

Leading companies within the nasal spray influenza vaccine market are concentrating on developing innovative formulations, such as live attenuated influenza vaccine, to boost immune responses and improve patient compliance. A live attenuated influenza vaccine (LAIV) consists of a flu vaccine formulated from live but weakened influenza viruses. It effectively prevents influenza by prompting the immune system to generate antibodies, thus offering protection without causing the illness itself. Furthermore, it delivers a broader immune response, encompassing both local and systemic immunity, thereby strengthening the body’s defenses against subsequent flu infections. As an example, in September 2024, AstraZeneca Plc, a UK-based pharmaceutical industry company, secured approval from the U.S. Food and Drug Administration (FDA) for FluMist, a live attenuated influenza vaccine (LAIV), enabling self-administration by adults aged up to 49 years or administration by caregivers to children aged 2 to 17 years. This makes it the first and only influenza vaccine approved for self- or caregiver-administration in the United States. This approval was founded on extensive usability studies demonstrating individuals’ capacity to correctly self-administer the vaccine, with 100% of participants delivering a full dose as instructed.

Which Global Companies Are Actively Competing In The Nasal Spray Influenza Vaccine Market?

Major companies operating in the nasal spray influenza vaccine market are Sanofi Pasteur SA, GSK plc, FluGen Inc., BioDiem Ltd, Codagenix Inc, Altimmune Inc, AstraZeneca PLC, MedImmune LLC, BCHT Biotechnology Co Ltd, Serum Institute of India Pvt Ltd, Vivaldi Biosciences, Vaccitech, Blue Water Vaccines, VaxInnate, INOVIO Pharmaceuticals, Cipla Ltd, Beijing Wantai Biological Pharmacy Enterprise Co Ltd, Bharat Biotech, Novavax Inc, BioNTech SE, Transgene SA, BiondVax Pharmaceuticals Ltd, Adimmune Corporation, Teva Pharmaceutical Industries Ltd

Read the full nasal spray influenza vaccine market report here:

https://www.thebusinessresearchcompany.com/report/nasal-spray-influenza-vaccine-global-market-report

What Are The Leading Geographic Regions In The Nasal Spray Influenza Vaccine Market?

North America was the largest region in the nasal spray influenza vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal spray influenza vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Nasal Spray Influenza Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24326&type=smp

Browse Through More Reports Similar to the Global Nasal Spray Influenza Vaccine Market 2026, By The Business Research Company

Chronic Rhinosinusitis With Nasal Polyps Global Market Report

https://www.thebusinessresearchcompany.com/report/chronic-rhinosinusitis-with-nasal-polyps-global-market-report

Nasal Splints Global Market Report

https://www.thebusinessresearchcompany.com/report/nasal-splints-global-market-report

Nasal Drug Delivery Technology Global Market Report

https://www.thebusinessresearchcompany.com/report/nasal-drug-delivery-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795